NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient

Ksenia Sevastianova; Jonathan Dean; Ciaran Bannan; Miriam Coghlan; Gillian Farrell; Catherine Murray; Cillian F De Gascun; Colm Bergin

doi:10.1016/j.jcv.2016.06.012

NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient

J Clin Virol. 2016 Sep:82:66-69. doi: 10.1016/j.jcv.2016.06.012. Epub 2016 Jun 23.

Authors

Ksenia Sevastianova¹, Jonathan Dean², Ciaran Bannan³, Miriam Coghlan³, Gillian Farrell³, Catherine Murray³, Cillian F De Gascun², Colm Bergin⁴

Affiliations

¹ Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland. Electronic address: [email protected].
² National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
³ Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
⁴ Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, Ireland.

PMID: 27454231
DOI: 10.1016/j.jcv.2016.06.012

Abstract

Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.

Keywords: Direct-acting antivirals; HCV genotype 1a; HIV; Ledipasvir; Resistance; Sofosbuvir.

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Drug Resistance, Viral*
Drug Therapy, Combination
Fluorenes / therapeutic use*
Genotype
HIV Infections / complications
HIV-1 / isolation & purification
Hepacivirus / classification*
Hepacivirus / genetics
Hepacivirus / isolation & purification
Hepatitis C, Chronic / complications
Hepatitis C, Chronic / drug therapy*
Humans
Liver Cirrhosis / drug therapy
Liver Cirrhosis / virology
Male
Middle Aged
Mutation, Missense
Ribavirin / therapeutic use*
Sofosbuvir / therapeutic use*
Treatment Failure
Viral Nonstructural Proteins / genetics

Substances

Antiviral Agents
Benzimidazoles
Fluorenes
Viral Nonstructural Proteins
ledipasvir
Ribavirin
NS-5 protein, hepatitis C virus
Sofosbuvir